| GTO ID | GTC3312 |
| Trial ID | NCT05688241 |
| Disease | Lymphoproliferative Disease | Lymphoma |
| Altered gene | EBV |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | EBV TCR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | Epstein-Barr Virus (EBV) -Specific T Memory Stem Cell (Tscm) Therapy to Treat EBV- Driven Lymphomas/ Diseases |
| Year | 2022 |
| Country | Switzerland |
| Company sponsor | University Hospital, Basel, Switzerland |
| Other ID(s) | 2022-01210; am22Khanna |
| Cohort 1 | |||||||||||
|
|||||||||||